Intravitreal triamcinolone acetonide versus bevacizumab therapy for macular edema associated with branch retinal vein occlusion

Yeo Jue Byun, Mi In Roh, Sungchul Lee, Hyoung Jun Koh

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Purpose To compare visual outcomes after intravitreal triamcinolone acetonide (IVTA) injection and intravitreal bevacizumab (IVB) administration for treatment of macular edema associated with branch retinal vein occlusion (BRVO). Methods A retrospective comparative case series of 134 consecutive patients that were treated with either IVTA or IVB for macular edema caused by BRVO. Visual acuity at baseline and 1, 3, 6, 9, and 12 months, and central macular thickness measured by OCT at baseline and 1, 3, 6, and 12 months. The time to recurrence of macular edema after treatment was also analyzed. Results Visual acuity (Snellen equivalent) improved significantly from 0.87 logMAR (0.14) to 0.49 logMAR (0.33) in the IVTA group, and from 0.91 logMAR (0.13) to 0.45 logMAR (0.36) in the IVB group 12 months after injection (p<0.001). Central macular thickness decreased significantly from 491.0 μm to 255.8 μm in the IVTA group, and from 477.4 μm to 218.9 μm in the IVB group 12 months after injection (p<0.001). In between-group comparisons, neither visual acuity (p=0.892) nor macular thickness (p= 0.612) improvements were statistically significantly different. In the IVTA-all group, recurrence of macular edema occurred in 7.6% of patients at a mean of 12.6 months postoperatively, and the average number of injections was 1.08. In the IVB-all group, 26.0% of patients suffered recurrences at a mean of 5.3 months after treatment, and received a mean of 1.89 injections. Recurrence was more frequent in the IVB group compared to the IVTA group (Kaplan-Meier survival analysis log-rank test, p<0.0001). Conclusions IVTA and IVB injections were similarly effective for improving visual acuity in patients with macular edema secondary to BRVO. However, the IVTA group showed longer mean improvement duration and less disease recurrence, and required fewer injections than the IVB group.

Original languageEnglish
Pages (from-to)963-971
Number of pages9
JournalGraefe's Archive for Clinical and Experimental Ophthalmology
Volume248
Issue number7
DOIs
Publication statusPublished - 2010 Jul 1

Fingerprint

Triamcinolone Acetonide
Retinal Vein Occlusion
Macular Edema
Intravitreal Injections
Visual Acuity
Recurrence
Injections
Therapeutics
Bevacizumab
Kaplan-Meier Estimate
Survival Analysis

All Science Journal Classification (ASJC) codes

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

@article{58478af71d1a44a18135239c8ab64570,
title = "Intravitreal triamcinolone acetonide versus bevacizumab therapy for macular edema associated with branch retinal vein occlusion",
abstract = "Purpose To compare visual outcomes after intravitreal triamcinolone acetonide (IVTA) injection and intravitreal bevacizumab (IVB) administration for treatment of macular edema associated with branch retinal vein occlusion (BRVO). Methods A retrospective comparative case series of 134 consecutive patients that were treated with either IVTA or IVB for macular edema caused by BRVO. Visual acuity at baseline and 1, 3, 6, 9, and 12 months, and central macular thickness measured by OCT at baseline and 1, 3, 6, and 12 months. The time to recurrence of macular edema after treatment was also analyzed. Results Visual acuity (Snellen equivalent) improved significantly from 0.87 logMAR (0.14) to 0.49 logMAR (0.33) in the IVTA group, and from 0.91 logMAR (0.13) to 0.45 logMAR (0.36) in the IVB group 12 months after injection (p<0.001). Central macular thickness decreased significantly from 491.0 μm to 255.8 μm in the IVTA group, and from 477.4 μm to 218.9 μm in the IVB group 12 months after injection (p<0.001). In between-group comparisons, neither visual acuity (p=0.892) nor macular thickness (p= 0.612) improvements were statistically significantly different. In the IVTA-all group, recurrence of macular edema occurred in 7.6{\%} of patients at a mean of 12.6 months postoperatively, and the average number of injections was 1.08. In the IVB-all group, 26.0{\%} of patients suffered recurrences at a mean of 5.3 months after treatment, and received a mean of 1.89 injections. Recurrence was more frequent in the IVB group compared to the IVTA group (Kaplan-Meier survival analysis log-rank test, p<0.0001). Conclusions IVTA and IVB injections were similarly effective for improving visual acuity in patients with macular edema secondary to BRVO. However, the IVTA group showed longer mean improvement duration and less disease recurrence, and required fewer injections than the IVB group.",
author = "Byun, {Yeo Jue} and Roh, {Mi In} and Sungchul Lee and Koh, {Hyoung Jun}",
year = "2010",
month = "7",
day = "1",
doi = "10.1007/s00417-010-1320-2",
language = "English",
volume = "248",
pages = "963--971",
journal = "Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie",
issn = "0065-6100",
publisher = "Springer Verlag",
number = "7",

}

Intravitreal triamcinolone acetonide versus bevacizumab therapy for macular edema associated with branch retinal vein occlusion. / Byun, Yeo Jue; Roh, Mi In; Lee, Sungchul; Koh, Hyoung Jun.

In: Graefe's Archive for Clinical and Experimental Ophthalmology, Vol. 248, No. 7, 01.07.2010, p. 963-971.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Intravitreal triamcinolone acetonide versus bevacizumab therapy for macular edema associated with branch retinal vein occlusion

AU - Byun, Yeo Jue

AU - Roh, Mi In

AU - Lee, Sungchul

AU - Koh, Hyoung Jun

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Purpose To compare visual outcomes after intravitreal triamcinolone acetonide (IVTA) injection and intravitreal bevacizumab (IVB) administration for treatment of macular edema associated with branch retinal vein occlusion (BRVO). Methods A retrospective comparative case series of 134 consecutive patients that were treated with either IVTA or IVB for macular edema caused by BRVO. Visual acuity at baseline and 1, 3, 6, 9, and 12 months, and central macular thickness measured by OCT at baseline and 1, 3, 6, and 12 months. The time to recurrence of macular edema after treatment was also analyzed. Results Visual acuity (Snellen equivalent) improved significantly from 0.87 logMAR (0.14) to 0.49 logMAR (0.33) in the IVTA group, and from 0.91 logMAR (0.13) to 0.45 logMAR (0.36) in the IVB group 12 months after injection (p<0.001). Central macular thickness decreased significantly from 491.0 μm to 255.8 μm in the IVTA group, and from 477.4 μm to 218.9 μm in the IVB group 12 months after injection (p<0.001). In between-group comparisons, neither visual acuity (p=0.892) nor macular thickness (p= 0.612) improvements were statistically significantly different. In the IVTA-all group, recurrence of macular edema occurred in 7.6% of patients at a mean of 12.6 months postoperatively, and the average number of injections was 1.08. In the IVB-all group, 26.0% of patients suffered recurrences at a mean of 5.3 months after treatment, and received a mean of 1.89 injections. Recurrence was more frequent in the IVB group compared to the IVTA group (Kaplan-Meier survival analysis log-rank test, p<0.0001). Conclusions IVTA and IVB injections were similarly effective for improving visual acuity in patients with macular edema secondary to BRVO. However, the IVTA group showed longer mean improvement duration and less disease recurrence, and required fewer injections than the IVB group.

AB - Purpose To compare visual outcomes after intravitreal triamcinolone acetonide (IVTA) injection and intravitreal bevacizumab (IVB) administration for treatment of macular edema associated with branch retinal vein occlusion (BRVO). Methods A retrospective comparative case series of 134 consecutive patients that were treated with either IVTA or IVB for macular edema caused by BRVO. Visual acuity at baseline and 1, 3, 6, 9, and 12 months, and central macular thickness measured by OCT at baseline and 1, 3, 6, and 12 months. The time to recurrence of macular edema after treatment was also analyzed. Results Visual acuity (Snellen equivalent) improved significantly from 0.87 logMAR (0.14) to 0.49 logMAR (0.33) in the IVTA group, and from 0.91 logMAR (0.13) to 0.45 logMAR (0.36) in the IVB group 12 months after injection (p<0.001). Central macular thickness decreased significantly from 491.0 μm to 255.8 μm in the IVTA group, and from 477.4 μm to 218.9 μm in the IVB group 12 months after injection (p<0.001). In between-group comparisons, neither visual acuity (p=0.892) nor macular thickness (p= 0.612) improvements were statistically significantly different. In the IVTA-all group, recurrence of macular edema occurred in 7.6% of patients at a mean of 12.6 months postoperatively, and the average number of injections was 1.08. In the IVB-all group, 26.0% of patients suffered recurrences at a mean of 5.3 months after treatment, and received a mean of 1.89 injections. Recurrence was more frequent in the IVB group compared to the IVTA group (Kaplan-Meier survival analysis log-rank test, p<0.0001). Conclusions IVTA and IVB injections were similarly effective for improving visual acuity in patients with macular edema secondary to BRVO. However, the IVTA group showed longer mean improvement duration and less disease recurrence, and required fewer injections than the IVB group.

UR - http://www.scopus.com/inward/record.url?scp=77955654660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955654660&partnerID=8YFLogxK

U2 - 10.1007/s00417-010-1320-2

DO - 10.1007/s00417-010-1320-2

M3 - Article

VL - 248

SP - 963

EP - 971

JO - Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie

JF - Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie

SN - 0065-6100

IS - 7

ER -